首页> 外文期刊>current surgery reports >Pediatric Small Bowel Transplantation
【24h】

Pediatric Small Bowel Transplantation

机译:小儿小肠移植

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Purpose of Review Small bowel transplantation is the only currently available option for children with permanent intestinal failure that can allow for full enteral nutrition. The aim of this article is to provide a comprehensive review of the indications, surgical technique, allograft types, perioperative management, and outcomes of children who undergo intestinal transplantation. Recent Findings Advancements in the management of immunosuppression and associated complications have been the most recent contributor to improved patient outcomes following intestinal transplantation. Most centers have adopted protocols that consist of maintenance therapy with tacrolimus following induction with a steroid bolus and either an IL-2 antagonist, rabbit antithymocyte globulin, or alemtuzumab. Some will eventually convert patients from tacrolimus to sirolimus for long-term maintenance. Improved viral detection methods have allowed for early detection and management of EBV-associated complications including PTLD. Novel methods for early and less invasive detection of acute cellular rejection may allow for decreased morbidity from this complication in the future. Summary While outcomes following intestinal transplantation have improved, they lag behind those for other solid organ transplants due to the high rate of immunologic complications found in this patient population. Future progress will depend on development of methods for earlier and more accurate detection of rejection, improvements in the detection and management of infection-related complications including PTLD, and on refinements in the management of chronic rejection.
机译:综述目的 小肠移植是目前唯一可用于永久性肠衰竭儿童的选择,可以提供完整的肠内营养。本文旨在全面回顾接受肠移植的儿童的适应症、手术技术、同种异体移植物类型、围手术期管理和结局。最新发现 免疫抑制和相关并发症管理的进展是改善肠移植后患者预后的最新贡献者。大多数中心采用的方案包括在诱导类固醇推注和 IL-2 拮抗剂、兔抗胸腺细胞球蛋白或阿仑珠单抗后使用他克莫司维持治疗。有些人最终会将患者从他克莫司转换为西罗莫司进行长期维持。改进的病毒检测方法使得早期发现和管理EBV相关并发症(包括PTLD)成为可能。早期和侵入性较小的急性细胞排斥反应的新方法可能会降低未来这种并发症的发病率。总结 虽然肠移植后的结果有所改善,但由于在该患者群体中发现的免疫并发症发生率很高,因此它们落后于其他实体器官移植。未来的进展将取决于开发早期和更准确地检测排斥反应的方法,改进感染相关并发症(包括PTLD)的检测和管理,以及改进慢性排斥反应的管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号